Mission Statement, Vision, & Core Values (2026) of Shenzhen YHLO Biotech Co., Ltd.

Founded in 2008 and trading on the Science and Technology Innovation Board as 688575.SS, Shenzhen YHLO Biotech has scaled from a focused IVD startup to a global diagnostics player offering over 300 products across multiple medical fields, exporting to nearly 115 countries with coverage exceeding 70% of China's top-tier hospitals; the company's R&D-led mission-investing more than 10% of annual revenue (about RMB 150 million in 2022)-is supported by research centers in Tokyo, Wuhan and Changsha, a production base in Xiangtan, and a patent portfolio of 681 patents (including 58 PCT filings), while quality credentials like ISO 9001, ISO 13485, KGMP and TGA plus FDA clearances for platforms such as the iFlash 3000 and HCG, regional service centers in the Middle East and Tunisia, and launches like the iBC 900 Biochemistry Analyzer underscore a vision to be a reliable, respected IVD enterprise grounded in core values of customer focus, innovation, quality and global collaboration.

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) - Intro

• To advance global health by delivering accurate, accessible, and innovative in vitro diagnostic (IVD) solutions.
• To empower clinicians and healthcare systems with rapid, reliable diagnostics that improve patient outcomes and public health preparedness.

• To be a world-leading IVD company recognized for scientific excellence, broad clinical impact, and trusted quality across hospitals and laboratories worldwide.
• To drive diagnostic innovation that enables precision medicine and scalable responses to infectious disease threats and chronic conditions.

• Scientific Rigor - sustained investment in R&D and protection of IP (681 patent filings as of 30 Aug 2024, including 58 PCT patents).
• Quality & Compliance - adherence to ISO 9001:2008, ISO 13485:2016, Korea KGMP, and Australia TGA standards.
• Global Reach & Accessibility - commitment to making diagnostics accessible across markets (exports to nearly 115 countries/regions).
• Clinical Partnership - focus on deep hospital penetration (coverage >70% in China's top-tier hospitals) and close collaboration with clinicians.
• Operational Excellence - scalable manufacturing and multi-site research to ensure supply continuity and technological leadership.

• Product breadth: over 300 IVD products spanning immunoassay, molecular diagnostics, clinical chemistry and other disciplines.
• Research & production network: research centers in Tokyo (Japan), Wuhan and Changsha (China), and a production base in Xiangtan (China).
• Intellectual property: 681 patent filings (367 invention, 167 utility model, 22 design, 58 PCT).
• Regulatory approvals and certifications: ISO 9001:2008, ISO 13485:2016, KGMP (Korea), TGA (Australia).

• Expand product registration across additional regulatory regions to increase the export footprint beyond ~115 markets.
• Accelerate PCT and invention patent conversions to safeguard core technologies and facilitate partnerships.
• Strengthen hospital penetration in second- and third-tier Chinese cities while scaling global distributor networks.

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) - Overview

Mission Statement: 'Focus on healthcare, better life with technology.' Shenzhen YHLO Biotech Co., Ltd. (688575.SS) centers its corporate purpose on improving global health outcomes by developing and deploying advanced diagnostic technologies.

• R&D commitment: YHLO invests over 10% of annual revenue into R&D - approximately RMB 150 million in 2022 (implying 2022 revenue of roughly RMB 1.5 billion based on that figure).
• Quality & regulatory credentials: ISO 13485 certified for its medical device quality management system; FDA clearances include products such as the iFlash 3000 and HCG assays.
• Global footprint: Established a Middle East Regional Service and Support Center and a Tunisia Sales & Service Office to improve regional access and after‑sales support.
• Product & collaboration advances: Launched the iBC 900 Biochemistry Analyzer and convened its first Global Distributor Conference to strengthen partner alignment and international distribution.

• Strategic emphasis: allocate sustained high-single-digit to low-double-digit percentage of revenues into R&D to accelerate assay portfolio expansion, automation platforms, and AI-enabled diagnostics.
• Market-facing initiatives: expand distributor networks and after-sales infrastructure via global conferences and regional service centers to reduce downtime and improve instrument utilization rates.

For deeper background on corporate history and governance, see: Shenzhen YHLO Biotech Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) - Mission Statement

• Building trust through certified quality systems (ISO 13485) and regulatory clearances (FDA) for core products.
• Expanding global presence via research centers and production bases to shorten product development cycles and ensure localized support.
• Driving technological advancement with new product launches such as the iBC 900 Biochemistry Analyzer and platform innovations like the iFlash 3000.

• Research centers: Tokyo (Japan), Wuhan (China), Changsha (China).
• Production base: Xiangtan (China).
• Global engagement: hosted its first Global Distributor Conference to deepen partnerships and accelerate market access.

• ISO 13485 certified quality management system-demonstrates conformity with global medical device manufacturing standards.
• FDA clearances for key products such as the iFlash 3000 immunoassay system and HCG assays-evidence of meeting stringent U.S. regulatory requirements.
• Recent product introduction: iBC 900 Biochemistry Analyzer-expands the company's IVD portfolio and addresses laboratory throughput needs.

• Regulatory approvals (FDA) and ISO certification underpin trust with international customers and payors, supporting the vision of being 'reliable and respected.'
• Multiple R&D centers and a dedicated production base reduce time-to-market for assays and analyzers and enable region-specific collaboration and support.
• Continued R&D spend and product diversification drive long-term resilience of the IVD portfolio against market and technology shifts.

Shenzhen YHLO Biotech Co., Ltd. (688575.SS) - Vision Statement

• Customer focused - designing platforms and reagent solutions tuned to clinical workflows and end-user needs.
• Hard working - scaling manufacturing capacity and supply chains to meet rising clinical demand without compromising lead times.
• Innovation - investing in automation, immunoassay and molecular diagnostics to expand diagnostic capability and throughput.
• Self-reflective - instituting continuous improvement loops across product development, post-market surveillance, and customer feedback.
• Quality of work - embedding international quality standards (ISO 13485) and regulatory best-practices across manufacturing and design.

• Strategic alliances: YHLO has established multiple strategic alliances with multinational corporations to broaden product portfolios and accelerate market entry.
• International research cooperation: in-depth collaborations with research partners across Europe, the USA, Japan, and Australia to co-develop advanced technologies and clinical evidence.
• Regulatory footprint: ISO 13485 certified; multiple product clearances including FDA clearance for the iFlash 3000 and HCG assays, supporting access to regulated markets.

• Product portfolio: Automated analyzers (e.g., iFlash series), immunoassays, molecular diagnostics and reagents designed for high-throughput hospital and laboratory settings.
• Regulatory pathway success: Demonstrated ability to meet stringent requirements (FDA, CE/IVD conformity and ISO 13485) - enabling export and adoption in regulated markets.
• Clinical adoption: Installed base expansion in large hospitals and third-party labs driven by combined analyzer+reagent consumable model.